TCT 2025: ShortCUT Trial Compares Cutting Balloon Angioplasty and Intravascular Lithotripsy (IVL) for Calcified Coronary Artery Disease
According to the Medical Dialogues Bureau at the TCT Conference 2025 in San Francisco, USA, cutting balloon angioplasty was found to be non-inferior to intravascular lithotripsy (IVL) in achieving optimal stent expansion for patients with moderate-to-severely calcified coronary lesions undergoing percutaneous coronary intervention (PCI).
The study also found that cutting balloon angioplasty offered similar procedural and clinical outcomes at a significantly lower procedural cost.
The ShortCUT trial is the first adequately powered, randomized controlled trial to compare intravascular lithotripsy to other balloon-based devices for the treatment of calcified coronary artery disease.
Cutting balloon angioplasty was found to be non-inferior to intravascular lithotripsy (IVL) in achieving optimal stent expansion.
Author's summary: TCT 2025 presents ShortCUT trial results comparing cutting balloon angioplasty and IVL for calcified coronary artery disease.
More News
- Art the Clown Owes One of His 'Terrifier' Actresses a Lot of Money
- Art the Clown Owes One of His 'Terrifier' Victims a Lot of Money
- Andreas Kaufer appointed as next ESO Director General
- 9 Black Actresses Who Went From Broadway To The Hollywood Big Screen
- Can MAGA Conservatives and Muslim Americans Unite?
- Tennis takes first loss in Sweet 16 - Davie County Enterprise Record
- US government inks $80 bn nuclear 'partnership' for AI
- NGP-backed Cygnet Energy to buy Kiwetinohk Energy for $1bn | PE Hub
- Banging bumper fun from 2000AD!
- New Map Catalogues Nationwide CA-Funded Factory Farm Gas Network